P
Pharming Group N.V. (PHGUF)
PNK – Real vaqt narxi. Valyuta: USD
1.10
0.00 (0.00%)
Bozor ochiq: Sep 8, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
PNK – Real vaqt narxi. Valyuta: USD
1.10
0.00 (0.00%)
Bozor ochiq: Sep 8, 2026, 4:00 PM EDT
Pharming Group N.V., biofarmatsevtika kompaniyasi, AQSh, Yevropa va xalqaro miqyosda kam uchraydigan kasalliklarni davolash uchun oqsil o'rnini bosuvchi terapiyalar va aniq dorilarni ishlab chiqadi va tijoratlashtiradi. Kompaniyaning asosiy mahsuloti RUCONEST, o'tkir irsiy angionevrotik shish (HAE) bilan og'rigan kattalar va o'smirlardagi o'tkir hujumlarni davolash uchun rekombinant C1 esteraza inhibitörü; va Joenja (leniolisib), faollashgan fosfoinozitid 3-kinaza delta sindromini davolash uchun og'iz orqali qabul qilinadigan kichik molekulali PI3Kδ inhibitörü. Kompaniya, shuningdek, Joenja, og'iz orqali qabul qilinadigan kichik molekulali PI3Kδ inhibitörünü ishlab chiqadi. Kompaniya Novartis bilan hamkorlik va litsenziya shartnomasiga ega. Pharming Group N.V. 1988 yilda tashkil etilgan va shtab-kvartirasi Niderlandiyaning Leyden shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Alexander Breidenbach M.B.A., Ph.D. | Chief Business Officer |
| Dr. Anurag Relan M.D., MPH | Chief Medical Officer |
| Dr. Magnus Hansson | Medical Director |
| Mr. Fabrice Chouraqui M.B.A., Ph.D., Pharm.D. | CEO & Executive Director |
| Mr. Kenneth Lynard EMBA, M.Sc. | Chief Financial Officer |
| Mr. Michael K. Levitan | VP of Investor Relations & Corporate Communications |
There is no data to display
| Mr. Ruud Van Outersterp L.L.M. | Chief Legal & Compliance Officer and Company Secretary |
| Ms. Ines Bernal B.A. | Chief People Officer |
| Ms. Leverne Marsh BPHARM | Chief Commercial Officer |
| Ms. Mireille Sanders M.Sc. | Chief Operations Officer |